{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/chlamydia-uncomplicated-genital/","result":{"data":{"firstChapter":{"id":"0b0636d2-117b-5108-b70c-d19a794db377","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field ce7ae9a0-2d7e-4af1-ae02-01668a81d59b --><h1>Chlamydia - uncomplicated genital: Summary</h1><!-- end field ce7ae9a0-2d7e-4af1-ae02-01668a81d59b -->","htmlStringContent":"<!-- begin item 5878bd46-c96f-4e38-8e4e-db03accbe796 --><!-- begin field e78d322e-c141-4485-ac68-b33e4f0e8bce --><ul><li>Genital chlamydia infection is the most common sexually transmitted bacterial infection in the UK.</li><li>In men, it infects the urethra. In women, it infects the endocervix or urethra, or both. It can also affect the conjunctiva, rectum, and nasopharynx.</li><li>At least 70% of women and 50% of men infected with <em>Chlamydia trachomatis</em> are asymptomatic.</li><li>Chlamydial infection is considered uncomplicated when the infection has not ascended to the upper genital tract. </li><li>Ascending chlamydial infection in women can cause pelvic inflammatory disease (PID).</li><li>The National Chlamydia Screening Programme recommends annual screening for all sexually active people younger than 25 years of age, or more frequently if they change their partner.</li><li>Tests for chlamydia are recommended if a sexually active person has the following symptoms and signs:<ul><li>In women: post-coital or intermenstrual bleeding, purulent vaginal discharge, mucopurulent cervical discharge, deep dyspareunia, dysuria, pelvic pain and tenderness, inflamed or friable cervix.</li><li>In men: dysuria, urethral discharge, urethral discomfort.</li></ul></li><li>Samples are taken by the following methods:<ul><li>In women: endocervical or vulvovaginal swab, or first-void urine sample.</li><li>In men: first-void urine sample or urethral swab.</li></ul></li><li>Treatment should be initiated promptly in all people who test positive for chlamydia, or have symptoms or signs strongly suggestive of chlamydia (after testing for other sexually transmitted infections [STIs] as appropriate). Ideally, the person should be referred to a genito-urinary medicine (GUM) clinic for treatment, screening for other STIs, the provision of detailed information on STIs, and partner notification. If the person declines, or is unable to attend a GUM clinic, they can be managed in primary care.</li><li>First-line treatment is doxycycline 100 mg twice a day for 7 days</li><li>In women who are pregnant or breastfeeding:<ul><li>Azithromycin 1 g daily for 1 day and then 500mg daily for 2 days, or</li><li>Amoxicillin 500 mg three times a day for 7 days, or</li><li>Erythromycin 500 mg four times a day for 7 days.</li></ul></li><li>The following information should be provided to people being managed in primary care:<ul><li>Written details of what chlamydia is, and how it is transmitted.</li><li>That it is important that sexual partners are evaluated and treated.</li><li>That sexual intercourse (including genital, oral, and anal sex, even with a condom) should be avoided until both the person and any sexual partners have completed the course of treatment. If azithromycin has been taken, advise sexual abstinence for 7 days after treatment, or until any sexual partners have completed their treatment.</li></ul></li><li>A test of cure is not usually necessary. However, it is recommended in pregnant women at least 3 weeks after completion of treatment. Test of cure (TOC) should also be undertaken for diagnosed rectal infections.</li><li><div>Repeat testing should be offered to all people under the age of 25 years diagnosed with chlamydia 3–6 months after completion of treatment to check for re-infection.</div></li><li><div>Repeat testing should also be considered for people over the age of 25 years who are at high risk of re-infection.</div></li></ul><!-- end field e78d322e-c141-4485-ac68-b33e4f0e8bce --><!-- end item 5878bd46-c96f-4e38-8e4e-db03accbe796 -->","topic":{"id":"9fd72b23-86c9-5ce5-bbdd-598398d0e8ea","topicId":"7ce33f6f-747f-41e5-b18b-09b2071a7d93","topicName":"Chlamydia - uncomplicated genital","slug":"chlamydia-uncomplicated-genital","aliases":[],"chapters":[{"id":"0b0636d2-117b-5108-b70c-d19a794db377","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"dda664e4-4864-5386-8bf2-ae38fe324071","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"6af905a1-8c41-53d9-b5ca-e96a0b2548be","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"84014645-1e22-51ca-b89b-52cd820d41b7","slug":"changes","fullItemName":"Changes"},{"id":"66fb5a16-c4f5-562e-9a73-84371e2bbe0d","slug":"update","fullItemName":"Update"}]},{"id":"82517c94-8e8a-5c62-b7d6-670ad4404258","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"0f150da5-1397-5e5d-b3dd-c9f2716423aa","slug":"goals","fullItemName":"Goals"},{"id":"f52e0aef-b3ad-5e13-b9ed-d426b4fa2f77","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ba38cbe0-ef08-5c56-a1f4-9a962b32ad9f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ced83fa-49d9-5243-8a7f-d942baa4bc1f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"5887995c-3455-537d-98cc-b1aeb54144ed","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0f2bffb-9529-57db-a995-191cba2d4e9f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"824044f0-a305-5a18-9a1d-bf36875a6ce8","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"5b8da5a2-6086-58db-9ad4-94fe2eb8bd48","slug":"definition","fullItemName":"Definition"},{"id":"ae31b546-618f-5b61-bf90-254c4868b504","slug":"prevalence","fullItemName":"Prevalence"},{"id":"8cd27f8c-d2f1-57ac-83e8-ed035b78ee51","slug":"risk-factors","fullItemName":"Risk Factors"},{"id":"ab8dc958-d4dc-5fef-ac7c-bc2b5865fdbe","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"3a69be68-2fd6-509b-85f4-164afc701ba8","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"a927a8de-387f-5d99-8924-b8836a37e1a0","slug":"screening-for-chlamydia-in-asymptomatic-men-women","fullItemName":"Screening for chlamydia in asymptomatic men and women"},{"id":"9da777e0-887a-5bb6-af7a-f6f0b986dbf4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"0a0b5d7a-0455-5688-90d5-253f427816b6","slug":"testing-to-confirm-the-diagnosis","fullItemName":"Testing to confirm the diagnosis"}]},{"id":"366e3be0-ac7e-5c90-baed-b3485d6e47ae","slug":"management","fullItemName":"Management","subChapters":[{"id":"9b3c090d-c63e-54c5-8cd1-1f401bc12c7b","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"e1354798-4643-56ab-8360-3c7075ebaa79","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"0cd2f484-1947-55ec-980e-1d0293ab355e","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"48da76f5-5041-504f-ab81-69b4fe7ff549","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"f100927d-5a5a-5112-bec9-59e5e4d4f040","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07eef3f6-7862-5fc9-b60f-ffa9d201996a","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"dacb6886-00ac-5160-9ee9-3ec19959d6ee","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"41a663fd-74e7-5b4b-b936-d4894268ff1f","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"34dd7d77-0b55-5661-b769-73e6cade3309","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"ffbef724-e30a-592a-836b-c4c5163d2e15","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0964fb39-dd03-54bb-af48-c376a46d685b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d69f8f7d-515f-5861-85b0-f5d6cf0ecfac","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2c32cb59-e5a3-5af2-b976-e11d73a2ea8a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87f9e401-f03f-547f-a524-e2f66bfb58c0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"69fd8a3f-633f-5092-85dd-f2220728872d","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"9fd72b23-86c9-5ce5-bbdd-598398d0e8ea","topicId":"7ce33f6f-747f-41e5-b18b-09b2071a7d93","topicName":"Chlamydia - uncomplicated genital","slug":"chlamydia-uncomplicated-genital","aliases":[],"topicSummary":"Genital chlamydia infection is the most common sexually transmitted bacterial infection in the UK.In men, it infects the urethra.","lastRevised":"Last revised in January 2021","nextPlannedReviewBy":"2021-06-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2021-05","nextPlannedReviewByDisplay":"May 2021","specialities":[{"id":"e174a859-759f-5b1d-898e-1a4155645e13","name":"Infections and infestations","slug":"infections-infestations"},{"id":"34b90622-9d68-500d-98a2-3c80efbae845","name":"Men's health","slug":"mens-health"},{"id":"f05d0400-7348-5229-ab3e-400d91618189","name":"Sexual health","slug":"sexual-health"},{"id":"0c813417-9691-5826-9371-c4bec6c53f06","name":"Women's health","slug":"womens-health"}],"chapters":[{"id":"0b0636d2-117b-5108-b70c-d19a794db377","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"dda664e4-4864-5386-8bf2-ae38fe324071","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"6af905a1-8c41-53d9-b5ca-e96a0b2548be","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"84014645-1e22-51ca-b89b-52cd820d41b7","slug":"changes","fullItemName":"Changes"},{"id":"66fb5a16-c4f5-562e-9a73-84371e2bbe0d","slug":"update","fullItemName":"Update"}]},{"id":"82517c94-8e8a-5c62-b7d6-670ad4404258","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"0f150da5-1397-5e5d-b3dd-c9f2716423aa","slug":"goals","fullItemName":"Goals"},{"id":"f52e0aef-b3ad-5e13-b9ed-d426b4fa2f77","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ba38cbe0-ef08-5c56-a1f4-9a962b32ad9f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ced83fa-49d9-5243-8a7f-d942baa4bc1f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"5887995c-3455-537d-98cc-b1aeb54144ed","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0f2bffb-9529-57db-a995-191cba2d4e9f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"824044f0-a305-5a18-9a1d-bf36875a6ce8","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"5b8da5a2-6086-58db-9ad4-94fe2eb8bd48","slug":"definition","fullItemName":"Definition"},{"id":"ae31b546-618f-5b61-bf90-254c4868b504","slug":"prevalence","fullItemName":"Prevalence"},{"id":"8cd27f8c-d2f1-57ac-83e8-ed035b78ee51","slug":"risk-factors","fullItemName":"Risk Factors"},{"id":"ab8dc958-d4dc-5fef-ac7c-bc2b5865fdbe","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"3a69be68-2fd6-509b-85f4-164afc701ba8","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"a927a8de-387f-5d99-8924-b8836a37e1a0","slug":"screening-for-chlamydia-in-asymptomatic-men-women","fullItemName":"Screening for chlamydia in asymptomatic men and women"},{"id":"9da777e0-887a-5bb6-af7a-f6f0b986dbf4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"0a0b5d7a-0455-5688-90d5-253f427816b6","slug":"testing-to-confirm-the-diagnosis","fullItemName":"Testing to confirm the diagnosis"}]},{"id":"366e3be0-ac7e-5c90-baed-b3485d6e47ae","slug":"management","fullItemName":"Management","subChapters":[{"id":"9b3c090d-c63e-54c5-8cd1-1f401bc12c7b","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"e1354798-4643-56ab-8360-3c7075ebaa79","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"0cd2f484-1947-55ec-980e-1d0293ab355e","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"48da76f5-5041-504f-ab81-69b4fe7ff549","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"f100927d-5a5a-5112-bec9-59e5e4d4f040","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07eef3f6-7862-5fc9-b60f-ffa9d201996a","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"dacb6886-00ac-5160-9ee9-3ec19959d6ee","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"41a663fd-74e7-5b4b-b936-d4894268ff1f","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"34dd7d77-0b55-5661-b769-73e6cade3309","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"ffbef724-e30a-592a-836b-c4c5163d2e15","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0964fb39-dd03-54bb-af48-c376a46d685b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d69f8f7d-515f-5861-85b0-f5d6cf0ecfac","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2c32cb59-e5a3-5af2-b976-e11d73a2ea8a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"87f9e401-f03f-547f-a524-e2f66bfb58c0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"69fd8a3f-633f-5092-85dd-f2220728872d","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"9fd72b23-86c9-5ce5-bbdd-598398d0e8ea"}},"staticQueryHashes":["3666801979"]}